Gregory Renza
Stock Analyst at Truist Securities
(4.08)
# 512
Out of 5,182 analysts
254
Total ratings
40.09%
Success rate
17.55%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Maintains: Buy | $36 → $33 | $13.50 | +144.44% | 14 | Apr 21, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $818 → $801 | $744.44 | +7.60% | 4 | Mar 31, 2026 | |
| ONC BeOne Medicines AG | Maintains: Buy | $400 → $412 | $298.90 | +37.84% | 4 | Feb 27, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $145 → $152 | $127.75 | +18.98% | 3 | Feb 11, 2026 | |
| CGON CG Oncology | Maintains: Buy | $66 → $75 | $66.82 | +12.24% | 6 | Feb 10, 2026 | |
| AMGN Amgen | Maintains: Hold | $318 → $319 | $340.18 | -6.23% | 19 | Jan 8, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $59 → $60 | $29.48 | +103.53% | 14 | Jan 6, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $32 → $38 | $24.43 | +55.55% | 8 | Dec 24, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Buy | $14 → $18 | $7.72 | +133.16% | 5 | Dec 11, 2025 | |
| CATX Perspective Therapeutics | Assumes: Buy | $8 → $12 | $4.27 | +181.03% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $23 → $30 | $16.49 | +81.93% | 12 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $13.10 | +121.37% | 10 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $4.56 | +141.23% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $104.04 | +34.56% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $2.63 | +242.21% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $10 | $4.77 | +109.64% | 4 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $23.37 | +118.23% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $111.90 | +25.11% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $45 → $50 | $44.65 | +11.98% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $22.30 | +16.59% | 16 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $3.76 | +112.77% | 12 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $5 | $1.17 | +327.35% | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $182 → $172 | $201.22 | -14.52% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $113 → $38 | $57.18 | -34.42% | 14 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $7.82 | +53.45% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $5.54 | +152.71% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $25.55 | -29.55% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $0.93 | +5,061.85% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $110 → $20 | $6.83 | +193.04% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $0.79 | +1,923.01% | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $14.42 | +1,148.27% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $0.86 | +9,190.44% | 5 | Mar 16, 2022 |
Viridian Therapeutics
Apr 21, 2026
Maintains: Buy
Price Target: $36 → $33
Current: $13.50
Upside: +144.44%
Regeneron Pharmaceuticals
Mar 31, 2026
Maintains: Buy
Price Target: $818 → $801
Current: $744.44
Upside: +7.60%
BeOne Medicines AG
Feb 27, 2026
Maintains: Buy
Price Target: $400 → $412
Current: $298.90
Upside: +37.84%
Gilead Sciences
Feb 11, 2026
Maintains: Buy
Price Target: $145 → $152
Current: $127.75
Upside: +18.98%
CG Oncology
Feb 10, 2026
Maintains: Buy
Price Target: $66 → $75
Current: $66.82
Upside: +12.24%
Amgen
Jan 8, 2026
Maintains: Hold
Price Target: $318 → $319
Current: $340.18
Upside: -6.23%
IDEAYA Biosciences
Jan 6, 2026
Maintains: Buy
Price Target: $59 → $60
Current: $29.48
Upside: +103.53%
Agios Pharmaceuticals
Dec 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $24.43
Upside: +55.55%
Fulcrum Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $14 → $18
Current: $7.72
Upside: +133.16%
Perspective Therapeutics
Nov 24, 2025
Assumes: Buy
Price Target: $8 → $12
Current: $4.27
Upside: +181.03%
Nov 24, 2025
Assumes: Buy
Price Target: $23 → $30
Current: $16.49
Upside: +81.93%
Nov 24, 2025
Initiates: Buy
Price Target: $29
Current: $13.10
Upside: +121.37%
Nov 24, 2025
Initiates: Buy
Price Target: $11
Current: $4.56
Upside: +141.23%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $104.04
Upside: +34.56%
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $2.63
Upside: +242.21%
Nov 24, 2025
Initiates: Hold
Price Target: $10
Current: $4.77
Upside: +109.64%
Nov 24, 2025
Initiates: Buy
Price Target: $51
Current: $23.37
Upside: +118.23%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $111.90
Upside: +25.11%
Jul 8, 2025
Downgrades: Sector Perform
Price Target: $45 → $50
Current: $44.65
Upside: +11.98%
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $22.30
Upside: +16.59%
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $3.76
Upside: +112.77%
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $1.17
Upside: +327.35%
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $201.22
Upside: -14.52%
Apr 16, 2025
Maintains: Sector Perform
Price Target: $113 → $38
Current: $57.18
Upside: -34.42%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $7.82
Upside: +53.45%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $5.54
Upside: +152.71%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $25.55
Upside: -29.55%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $0.93
Upside: +5,061.85%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $110 → $20
Current: $6.83
Upside: +193.04%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $0.79
Upside: +1,923.01%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $14.42
Upside: +1,148.27%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $0.86
Upside: +9,190.44%